Drug Search Results
More Filters [+]

Seviteronel

Alternative Names: seviteronel, VT464, VT-464, VT 464
Latest Update: 2023-11-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CYP17 Inhibitor,AR Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Innocrin
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Seviteronel

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Anal Gland Cancer|Neck Pain|Prostate Cancer|Salivary Gland Cancer|Bladder Cancer|Low Back Pain|Head and Neck Cancer|Renal Cell Carcinoma|Small Cell Sarcoma|Breast Cancer|Thyroid Cancer|Goodpasture Syndrome|Small Cell Carcinoma|Melanoma|Glioblastoma|Basal Cell Carcinoma|Triple Negative Breast Cancer|Male Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

4CAST

P2

Recruiting

Triple Negative Breast Cancer

2024-07-01

START

P2

Terminated

Glioblastoma|Small Cell Sarcoma|Head and Neck Cancer|Renal Cell Carcinoma|Breast Cancer|Goodpasture Syndrome|Anal Gland Cancer|Salivary Gland Cancer|Melanoma|Basal Cell Carcinoma|Low Back Pain|Small Cell Carcinoma|Neck Pain|Prostate Cancer|Thyroid Cancer|Bladder Cancer

2021-02-28

2011-004103-20

P2

Completed

Prostate Cancer

2019-01-23

CLARITY-01

P2

Completed

Triple Negative Breast Cancer|Male Breast Cancer

2019-01-01

Recent News Events